[Form 4] Equillium, Inc. Insider Trading Activity
Equillium, Inc. (EQ) reporting person Stephen Connelly, Chief Scientific Officer and Director, received an employee stock option award covering 1,025,000 shares on 08/29/2025 with an exercise price of $1.74. The filing shows the option as acquired (code A) and lists 1,025,000 shares beneficially owned following the transaction. The explanatory note states standard time-based vesting: 25% vest on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter.
Equillium, Inc. (EQ) la persona segnalante Stephen Connelly, Chief Scientific Officer e membro del consiglio, ha ricevuto un premio di opzioni su azioni riservate ai dipendenti per 1.025.000 azioni in data 29/08/2025 con prezzo di esercizio di $1,74. La comunicazione riporta l'opzione come acquisita (codice A) e indica la detenzione beneficiaria di 1.025.000 azioni a seguito della transazione. La nota esplicativa specifica il consueto piano di maturazione basato sul tempo: il 25% matura al primo anniversario della data di inizio del vesting e il restante viene maturato in 36 rate mensili uguali successivamente.
Equillium, Inc. (EQ) la persona informante Stephen Connelly, Director Cient铆fico y miembro del consejo, recibi贸 una adjudicaci贸n de opciones sobre acciones para empleados por 1.025.000 acciones el 29/08/2025 con un precio de ejercicio de $1,74. La presentaci贸n muestra la opci贸n como adquirida (c贸digo A) y enumera 1.025.000 acciones en propiedad beneficiaria tras la transacci贸n. La nota explicativa indica el habitual calendario de consolidaci贸n por tiempo: el 25% se consolida en el primer aniversario del inicio del periodo de vesting y el resto se consolida en 36 cuotas mensuales iguales posteriormente.
Equillium, Inc. (EQ) 氤搓碃鞛� Stephen Connelly(Chief Scientific Officer 氚� 鞚挫偓)電� 2025-08-29鞐� 歆侅洂 鞀ろ啞鞓奠厴鞙茧 1,025,000欤�毳� 攵�鞐皼鞎橃溂氅�, 頄夓偓臧�瓴╈潃 $1.74鞛呺媹雼�. 鞝滌稖靹滊電� 頃措嫻 鞓奠厴鞚� 旆摑霅� 瓴冹溂搿� 響滌嫓(旖旊摐 A)頃橁碃 瓯半灅 頉� 1,025,000欤�毳� 鞁れ 氤挫湢頃橁碃 鞛堧姅 瓴冹溂搿� 旮办灛頃橁碃 鞛堨姷雼堧嫟. 靹る獏霝�鞐愲姅 鞚茧皹鞝侅澑 鞁滉皠 旮半皹 臧�靻�(氩犾姢韺�) 臁瓣贝鞚� 氇呾嫓霅橃柎 鞛堨溂氅�: 氩犾姢韺� 鞁滌瀾鞚茧攵�韯� 1雲勳Ц鞐� 25%臧� 氩犾姢韸鸽悩瓿� 雮橂ǜ歆�電� 鞚错泟 36臧滌洈鞐� 瓯胳硱 毵れ洈 霃欖澕頃� 牍勳湪搿� 氩犾姢韸鸽惄雼堧嫟.
Equillium, Inc. (EQ) la personne d茅clarante Stephen Connelly, Chief Scientific Officer et administrateur, a re莽u une attribution d'options d'achat d'actions pour employ茅s de 1 025 000 actions le 29/08/2025 avec un prix d'exercice de 1,74 $. la d茅claration indique l'option comme acquise (code A) et liste 1 025 000 actions d茅tenues b茅n茅ficiairement apr猫s la transaction. La note explicative pr茅cise le calendrier standard de acquisition fond茅 sur le temps聽: 25聽% acqui猫rent droit au premier anniversaire de la date de d茅but du vesting et le reste s'acquiert en 36 versements mensuels 茅gaux ensuite.
Equillium, Inc. (EQ) meldende Person Stephen Connelly, Chief Scientific Officer und Direktor, erhielt am 29.08.2025 eine Mitarbeiteraktien-Optionszuteilung 眉ber 1.025.000 Aktien mit einem Aus眉bungspreis von $1,74. Die Meldung f眉hrt die Option als erworben (Code A) und gibt nach der Transaktion 1.025.000 Aktien als wirtschaftlich gehalten an. Die erl盲uternde Anmerkung beschreibt die 眉bliche zeitbasierte Vesting-Regelung: 25% werden am ersten Jahrestag des Vesting-Beginns f盲llig, der Rest vestet anschlie脽end in 36 gleichen monatlichen Raten.
- Significant retention incentive: Large time鈥慴ased option grant aligns the Chief Scientific Officers interests with long鈥憈erm shareholder value.
- Standard vesting pattern: 25% after one year and monthly vesting thereafter supports retention over a multi鈥憏ear period.
- Potential dilution: Grant of 1,025,000 shares could be dilutive depending on total outstanding shares (outstanding share count not provided).
- Key details missing: The filing does not state the vesting commencement date, market price at grant, or whether any performance conditions apply.
Insights
TL;DR: A large time鈥慴ased option grant to a senior officer aligns incentives but creates potential dilution; vesting schedule is standard.
The 1,025,000鈥憇丑补谤别 option award to the Chief Scientific Officer and Director is a meaningful equity grant that ties long鈥憈erm executive incentives to company performance. The disclosed vesting structure鈥�25% after one year, then monthly over three years鈥攊s conventional for retention. From governance perspective, materiality depends on EQ's outstanding share count (not provided in this filing). The filing is a routine disclosure under Section 16 and does not disclose cash compensation, prior grants, or any performance conditions.
TL;DR: Substantial option quantity at $1.74 strike could be highly valuable if share price rises, but current grant economics cannot be assessed here.
This Form 4 records acquisition of an employee stock option for 1,025,000 underlying shares with a $1.74 exercise price. The document provides the vesting cadence but omits the vesting commencement date and the company alance sheet or market price context, so intrinsic value and dilution impact cannot be calculated from this filing alone. No performance vesting or accelerated vesting terms are disclosed in the explanation provided.
Equillium, Inc. (EQ) la persona segnalante Stephen Connelly, Chief Scientific Officer e membro del consiglio, ha ricevuto un premio di opzioni su azioni riservate ai dipendenti per 1.025.000 azioni in data 29/08/2025 con prezzo di esercizio di $1,74. La comunicazione riporta l'opzione come acquisita (codice A) e indica la detenzione beneficiaria di 1.025.000 azioni a seguito della transazione. La nota esplicativa specifica il consueto piano di maturazione basato sul tempo: il 25% matura al primo anniversario della data di inizio del vesting e il restante viene maturato in 36 rate mensili uguali successivamente.
Equillium, Inc. (EQ) la persona informante Stephen Connelly, Director Cient铆fico y miembro del consejo, recibi贸 una adjudicaci贸n de opciones sobre acciones para empleados por 1.025.000 acciones el 29/08/2025 con un precio de ejercicio de $1,74. La presentaci贸n muestra la opci贸n como adquirida (c贸digo A) y enumera 1.025.000 acciones en propiedad beneficiaria tras la transacci贸n. La nota explicativa indica el habitual calendario de consolidaci贸n por tiempo: el 25% se consolida en el primer aniversario del inicio del periodo de vesting y el resto se consolida en 36 cuotas mensuales iguales posteriormente.
Equillium, Inc. (EQ) 氤搓碃鞛� Stephen Connelly(Chief Scientific Officer 氚� 鞚挫偓)電� 2025-08-29鞐� 歆侅洂 鞀ろ啞鞓奠厴鞙茧 1,025,000欤�毳� 攵�鞐皼鞎橃溂氅�, 頄夓偓臧�瓴╈潃 $1.74鞛呺媹雼�. 鞝滌稖靹滊電� 頃措嫻 鞓奠厴鞚� 旆摑霅� 瓴冹溂搿� 響滌嫓(旖旊摐 A)頃橁碃 瓯半灅 頉� 1,025,000欤�毳� 鞁れ 氤挫湢頃橁碃 鞛堧姅 瓴冹溂搿� 旮办灛頃橁碃 鞛堨姷雼堧嫟. 靹る獏霝�鞐愲姅 鞚茧皹鞝侅澑 鞁滉皠 旮半皹 臧�靻�(氩犾姢韺�) 臁瓣贝鞚� 氇呾嫓霅橃柎 鞛堨溂氅�: 氩犾姢韺� 鞁滌瀾鞚茧攵�韯� 1雲勳Ц鞐� 25%臧� 氩犾姢韸鸽悩瓿� 雮橂ǜ歆�電� 鞚错泟 36臧滌洈鞐� 瓯胳硱 毵れ洈 霃欖澕頃� 牍勳湪搿� 氩犾姢韸鸽惄雼堧嫟.
Equillium, Inc. (EQ) la personne d茅clarante Stephen Connelly, Chief Scientific Officer et administrateur, a re莽u une attribution d'options d'achat d'actions pour employ茅s de 1 025 000 actions le 29/08/2025 avec un prix d'exercice de 1,74 $. la d茅claration indique l'option comme acquise (code A) et liste 1 025 000 actions d茅tenues b茅n茅ficiairement apr猫s la transaction. La note explicative pr茅cise le calendrier standard de acquisition fond茅 sur le temps聽: 25聽% acqui猫rent droit au premier anniversaire de la date de d茅but du vesting et le reste s'acquiert en 36 versements mensuels 茅gaux ensuite.
Equillium, Inc. (EQ) meldende Person Stephen Connelly, Chief Scientific Officer und Direktor, erhielt am 29.08.2025 eine Mitarbeiteraktien-Optionszuteilung 眉ber 1.025.000 Aktien mit einem Aus眉bungspreis von $1,74. Die Meldung f眉hrt die Option als erworben (Code A) und gibt nach der Transaktion 1.025.000 Aktien als wirtschaftlich gehalten an. Die erl盲uternde Anmerkung beschreibt die 眉bliche zeitbasierte Vesting-Regelung: 25% werden am ersten Jahrestag des Vesting-Beginns f盲llig, der Rest vestet anschlie脽end in 36 gleichen monatlichen Raten.
FAQ
What did Equillium (EQ) insider Stephen Connelly acquire?
What is the vesting schedule for the option reported on the Form 4?
Does the Form 4 show how many shares Stephen Connelly owns after the transaction?
What is the exercise price and transaction date of the option?
Are there performance conditions or the vesting commencement date disclosed?
